Multidrug Resistant Coagulase-Positive *Staphylococcus aureus* and Their Enterotoxins Detection in Traditional Cheeses Marketed in Banat Region, Romania

Adriana Morar 1, Alexandra Ban-Cucerzan 1, Viorel Herman 2, Emil Tîrziu 1, Khalid Ibrahim Sallam 3, Samir Mohammed Abd-Elghany and Kálmán Imre 1, 4, *©* 2021 by the authors. Licensee MDPI, Basel, Switzerland.

**Abstract:** The main objectives of the present study were to determine the occurrence of coagulase-positive staphylococci (CPS) and to assess the presence and antimicrobial susceptibility profile of *Staphylococcus aureus* isolates in different raw milk origin (cow and sheep) traditional cheeses marketed in Banat region, Romania. Additionally, the presence of *mecA* gene in *S. aureus* isolates and the staphylococcal enterotoxins (SEs) in cheese samples were evaluated. A total of 81.6% (138/169) of the screened samples were positive for CPS. Furthermore, 35.5% (49/138) of the investigated CPS positive cheese samples were contaminated with *S. aureus*, with an isolation frequency of 46.6% (14/30) in casei, 33.3% (32/96) in telemea, 25% (2/8) in burduf, and 25% (1/4) in urdă assortments, respectively. From the total number of *S. aureus* isolates, 6.1% (3/49) harbored the *mecA* gene. Detectable levels of SEs were identified in 4.3% (4/94) of cheese samples with a CPS contamination level higher than 10^5^ log CFU g⁻¹. The expressed antimicrobial susceptibility profile of the tested cheese-origin *S. aureus* isolates, with the automated Vitek 2 equipment, showed resistance towards amikacin (90.1%, 10 out from 11 tested), enrofloxacin (86.2%, 25/29), ceftiofur (72.7%, 8/11), neomycin (63.6%, 7/11), benzylpenicillin (53.1%, 26/49), kanamycin (41.4%, 12/29), rifampicin (39.5%, 15/38), ampicillin (38.8%, 19/49), tilmicosin (36.4%, 4/11), clindamycin (30.6%, 15/49), ciprofloxacin (30%, 6/20), erythromycin (22.4%, 11/49), tylosin (18.2%, 2/11), oxacillin (16.3%, 8/49), linezolid (15%, 3/20), teicoplanin (15%, 3/20), fusidic acid (13.1%), imipenem (10.5%, 4/38), vancomycin (7.9%, 3/38), ampicillin (5.5%, 1/18), mupirocin (5.5%, 1/18), fosfomycin (5%, 1/20), and gentamicin (4.1%, 2/49). Twenty-four (49%) *S. aureus* isolates exhibited multidrug resistance. The investigation highlighted a common occurrence of multidrug-resistant *S. aureus* strains in the monitored cheese assortments, which can constitute a potential risk for consumers' health.

**Keywords:** coagulase-positive staphylococci; multidrug resistant *S. aureus*; staphylococcal enterotoxins; traditional cheeses

1. **Introduction**

*Staphylococcus aureus* subsp. *aureus*, the main representative species of the coagulase-positive staphylococci, is a Gram positive, nonmotile, facultative anaerobic, ubiquitous bacteria throughout nature. This microorganism, having natural ecological niches in the nasal cavity and skin of warm-blooded animals, is considered a leading cause of several health-care-associated infections (e.g., skin and soft tissue abscesses, endocarditis,
osteomyelitis, bacteraemia). In addition, its toxic shock syndrome and food poisoning effect in humans, resulting from the ingestion of the produced thermostable and pepsin-resistant enterotoxins in a certain food matrix, has also been well documented [1]. In milk producing animals, *S. aureus* often colonizes the ductus papillaris of the mammary glands, which can result in the frequent appearance of clinical or subclinical mastitis phenomenon, generating reasons for antimicrobial use in dairy industry [2].

The production of traditional raw milk cheeses in the backyard and/or small-scale integrated livestock at farm level, and their direct sale to the final consumer within agri-food markets has a long and very popular cultural heritage in Romania, passed from generation to generation, offering a decent income for farmers. The microbiological safety of these products is closely linked to the successful implementation of food safety management systems within the production–storage–dispatch–marketing chain by farmhouse cheesemakers, as opposed to industrially produced cheese assortments whose safety is guaranteed by the manufacturer through authorized veterinary personnel. Nevertheless, several recently conducted studies in the surrounding Balkan Peninsula region, in countries with traditional cheese manufacturing history [3–6], demonstrated that raw milk cheese can harbor enterotoxin producing *S. aureus* strains. In addition, in the last decade, the involvement of the raw milk cheese origin staphylococcal toxins in food-borne outbreaks in several European Union (EU) member states (e.g., France, Italy, Hungary) has been frequently highlighted in the annually published European Food Safety Authority (EFSA) and European Centre for Disease Prevention and Control (ECDC) scientific reports [7].

Nowadays, the foodborne antimicrobial resistance (FAMR) phenomenon is an increasing biological hazard, as a consequence of irrational decades-long usage of antimicrobials. Based on the One Health concept, to prevent the propagation of drug-resistant bacteria and to achieve better public health outcomes, an integrated AMR surveillance system along the food chain is recommended [7]. In this regard, in Romania, limited information is available concerning the study of the occurrence and antimicrobial susceptibility profile of the methicillin-resistant *S. aureus* (MRSA) strains in different food products [8,9], demonstrating the potential role of the screened food matrices in the transmission, colonization, and infection of the pathogen lineages among humans.

Considering the lack of any available scientific peer reviewed publications, the present survey aimed to determine the occurrence of coagulase positive staphylococci (CPS), and to assess the presence and antimicrobial susceptibility profile of *S. aureus* isolates in different raw milk origin traditional cheeses, marketed in Banat region, Romania. Additionally, the presence of *mecA* gene in *S. aureus* isolates and the staphylococcal enterotoxins in cheese samples were evaluated.

2. Results

2.1. Frequency of Isolation and Contamination Level of CPS, and Incidence of *S. aureus*

Of the 169 traditional raw milk origin cheese samples examined, 138 (81.6%; 95% CI 75.1–86.7) were contaminated with CPS, with a distribution of 101 (83.5% from the total of 121; 95% CI 75.8–89.0) and 37 (77.1% from the total of 48; 95% CI 63.5–86.7) positive samples in the periods of February 2012–October 2013, and January 2020–February 2021, respectively. Concerning the examined cheese categories, the highest frequency of isolation was recorded in telemea samples (88.1%; 96/109, 95% CI 80.6–92.9), followed by cas (78.9%; 30/38, 95% CI 63.6–88.9), burduf (72.7%; 8/11, 95% CI 43.4–90.3), and urdă (36.4%; 4/11, 95% CI 15.1–64.6) assortments. These differences are not statistically significant (*p* > 0.05). The detailed distribution of CPS in cheese samples according to the milk origin (sheep or cow), as well as the registered minimum, maximum, and mean values in each assortment are presented in Table 1.
Table 1. Presence of coagulase positive staphylococci (CPS), *S. aureus* and staphylococcal enterotoxins in the investigated traditional raw milk origin cheeses in Banat region, Romania.

| Cheese Assortments and Their Origin (No. of Examined) | No. of Samples Containing CPS (%) | CPS Levels of Contamination (log CFU/g⁻¹) | No. of CPS Positive Samples Containing *S. aureus* (%) | No. of *S. aureus* with mecA Gene (%) | No. of Cheese Samples with Enterotoxins/Tested (%) |
|-----------------------------------------------------|-----------------------------------|------------------------------------------|-------------------------------------------------------|--------------------------------------|-----------------------------------------------|
|                                                     |                                   | Below the Regulatory [10] Limit ≤ 10⁵ | Above the Regulatory Limit > 10⁵ | Mean ± SD                             |                                |                                |
|                                                     |                                   | Min. | Max. | No. (%) | Min. | Max. | No. (%) | Min. | Max. | No. (%) | Min. | Max. | No. (%) | Min. | Max. | No. (%) |
| **telemea**                                         | sheep milk (n = 77)               | 71 (92.2) | 3.26 | 4.91 | 11 (15.5) | 5.51 | 7.12 | 60 (84.5) | 5.67 ± 0.85 | 24 (33.8) | 2 (8.3) | 1/60 (1.7) |
|                                                     | cow milk (n = 32)                 | 25 (78.1) | 2.37 | 4.81 | 18 (72.0) | 5.00 | 7.14 | 7 (28.0) | 4.19 ± 1.40 | 8 (32.0) | - | 1/7 (14.3) |
| **caș**                                             | sheep milk (n = 20)               | 17 (85.0) | 4.15 | 4.62 | 4 (23.5) | 5.38 | 7.06 | 13 (76.5) | 5.66 ± 0.92 | 6 (35.3) | 1 (16.6) | 2/13 (15.4) |
|                                                     | cow milk (n = 18)                 | 13 (72.2) | 2.61 | 4.75 | 6 (46.2) | 5.26 | 6.36 | 7 (53.8) | 4.80 ± 1.19 | 8 (61.5) | - | 0/7 |
| **burduf**                                          | sheep milk (n = 11)               | 8 (72.7) | 4.61 | 4.80 | 3 (37.5) | 5.41 | 7.26 | 5 (62.5) | 5.83 ± 1.07 | 2 (25.0) | - | 0/5 |
|                                                     | urdă sheep milk (n = 11)          | 4 (36.4) | 3.62 | 4.48 | 2 (50.0) | 6.86 | 7.32 | 2 (50.0) | 5.57 ± 1.79 | 1 (25.0) | - | 0/2 |
| **Overall (n = 169)**                               |                                   | 138 (81.6) | N.A. | N.A. | 44 (31.9) | N.A. | N.A. | 94 (68.1) | N.A. | 49 (35.5) | 3 (6.1) | 4/94 (4.3) |

Legend: No.—number; Min.—minimum; Max.—maximum; SD—standard deviation, N.A.—not applicable.
Of the 138 CPS positive cheese samples, 49 (35.5%, 95% CI 28.0–43.8) were contaminated with S. aureus. Out of them, 38 (37.6% from the total of 101; 95% CI 28.8–47.4) samples were obtained in the study period February 2012–October 2013, and another 11 (29.7% from total of 37; 95% CI 17.5–45.8) samples in the period January 2020–February 2021, with an isolation frequency of 37.6% and 29.7%, respectively. Their overall distribution according to the tested assortments were 46.6%, 33.3%, 25.0%, and 25.0% in ças, telemea, burduf, and urdă samples, respectively (Table 1). These differences are not statistically significant (p > 0.05).

2.2. Prevalence of Genetic Markers among the Isolated S. aureus Strains

Both 16S rDNA and nuc genes were detected in all (49) S. aureus isolates tested, confirming the results of their biochemical testing with the Vitek2 system. From the total number of isolates, three (6.1%; 95% CI 2.1–16.5) harbored the mecA gene, being recovered from two (8.3%) telemea and one (16.6%) ças assortments in the period of January 2020–February 2021 (Table 1). These isolates were accounted as methicillin-resistant, because the detection of this gene represents the standard procedure in the determining resistance towards methicillin. It is important to mention that in the case of MRSA strains, from the total genome, ~25% can consist on the presence of mobile genetic elements (e.g., bacteriophages, plasmids, transposoms, pathogenicity islands, or chromosomal cassettes) constituting the so-called accessory genome, responsible for genetic material transfer between strains (reviewed by [1]).

2.3. Detection of SEs in Cheese Samples

Detectable levels of SEs were identified in four (4.3%, 95% CI 1.7–10.4) out of 94 tested cheese samples with a CPS contamination level higher than 10^5 log CFU g^-1 (Table 1). All of these positive findings were obtained in the study period of February 2012–October 2013.

2.4. Antimicrobial Resistance Profile of S. aureus Isolated Strains

Antimicrobial resistance profile of the tested S. aureus strains (n = 49), according to their isolation sources, are summarized in Table 2. In addition, the antimicrobial susceptibility test results according to the used specific bacteria cards, are available in the Supplementary Materials.
Table 2. Antimicrobial resistance profile of the tested *S. aureus* strains (n = 49) according to their isolation sources.

| Antimicrobial Class | Agent | Sheep Milk | Cow Milk | Total |
|---------------------|-------|------------|----------|-------|
|                     |       | Telemea    | Caş      | Urdă  | Telemea | Caş |
| β-lactams           | PCG   | 15/24 (62.5%) | 2/6 (33.3%) | 1/2 (50%) | 1/1 (100%) | 5/8 (62.5%) | 2/8 (25%) | 26/49 (53.1%) |
|                     | OXA   | 6/24 (25%) | 1/6 (16.7%) | 0/2 (0%) | 0/1 (0%) | 0/8 (0%) | 1/8 (12.5%) | 8/49 (16.3%) |
|                     | AMP   | 1/16 (6.3%) | 0/2 (0%) | N.A. | N.A. | 0/8 (0%) | 0/3 (0%) | 1/29 (3.4%) |
|                     | IPM   | 3/18 (16.7%) | 1/6 (16.7%) | 0/2 (0%) | 0/1 (0%) | 0/5 (0%) | 0/6 (0%) | 4/38 (10.5%) |
|                     | SAM   | 0/10 (0%) | 0/2 (0%) | N.A. | N.A. | 0/5 (0%) | 0/1 (0%) | 0/18 (0%) |
|                     | CET   | 0/6 (0%) | N.A. | N.A. | N.A. | 0/3 (0%) | 0/2 (0%) | 0/11 (0%) |
|                     | CTF * | 4/6 (66.7%) | N.A. | N.A. | N.A. | 3/3 (100%) | 1/2 (50%) | 8/11 (72.7%) |
|                     | CEF   | 0/6 (0%) | N.A. | N.A. | N.A. | 0/3 (0%) | 0/2 (0%) | 0/11 (0%) |
| aminoglycosides     | GEN   | 1/24 (4.2%) | 0/6 (0%) | 0/2 (0%) | 0/1 (0%) | 0/8 (0%) | 1/8 (12.5%) | 2/49 (4.1%) |
|                     | KAN   | 7/16 (43.8%) | 0/2 (0%) | N.A. | N.A. | 3/8 (37.5%) | 2/3 (66.7%) | 12/29 (41.4%) |
|                     | AMK   | 5/6 (83.3%) | N.A. | N.A. | N.A. | 3/3 (100%) | 2/2 (100%) | 10/11 (90.9%) |
|                     | NEO * | 3/6 (50%) | N.A. | N.A. | N.A. | 3/3 (100%) | 1/2 (50%) | 7/11 (63.6%) |
| quinolones          | CIP * | 2/8 (25%) | 2/4 (50%) | 0/2 (0%) | 0/1 (0%) | N.A. | 2/5 (40%) | 6/20 (30.0%) |
|                     | MXF   | 0/8 (0%) | 0/4 (0%) | 0/2 (0%) | 0/1 (0%) | N.A. | 0/5 (0%) | 0/20 (0%) |
|                     | ENR   | 15/16 (93.8%) | 2/2 (100%) | N.A. | N.A. | 5/8 (62.5%) | 3/3 (100%) | 25/29 (86.2%) |
| steroids            | FA    | 3/18 (16.7%) | 2/6 (33.3%) | 0/2 (0%) | 0/1 (0%) | 0/5 (0%) | 0/6 (0%) | 5/38 (13.2%) |
| glycopeptides       | TEC * | 2/8 (25%) | 1/4 (25%) | 0/2 (0%) | 0/1 (0%) | N.A. | 2/5 (40%) | 5/20 (25.0%) |
|                     | VAN   | 2/8 (25%) | 1/6 (16.7%) | 0/2 (0%) | 0/1 (0%) | 0/5 (0%) | 0/6 (0%) | 3/38 (7.9%) |
| lincomycins         | CLI   | 8/24 (33.3%) | 2/6 (33.3%) | 0/2 (0%) | 0/1 (0%) | 3/8 (37.5%) | 2/8 (25%) | 15/49 (30.6%) |
| macrolides          | ERY   | 6/24 (25%) | 1/6 (16.7%) | 0/2 (0%) | 0/1 (0%) | 3/8 (37.5%) | 1/8 (12.5%) | 11/49 (22.4%) |
|                     | TMS   | 2/6 (33.3%) | N.A. | N.A. | N.A. | 1/3 (33.3%) | 1/2 (50%) | 4/11 (36.4%) |
|                     | TYL   | 1/6 (16.7%) | N.A. | N.A. | N.A. | 0/3 (0%) | 1/2 (50%) | 2/11 (18.2%) |
Table 2. Cont.

| Antimicrobial Class | Antimicrobial Agent | No. of Tested S. aureus Strains according to Their Origin | No. of Resistant S. aureus/No. of Total S. aureus Strains Tested (%) | Total |
|---------------------|---------------------|--------------------------------------------------------|-------------------------------------------------------------------|-------|
|                     |                     | Sheep Milk | Burdur | Urdă | Telemea | Caş |
| oxazolidinones      | LZD                 |            |        |       |         |     | 2/8 (25%) | 1/4 (25%) | 0/2 (0%) | 0/1 (0%) | N.A. | 0/5 (0%) | 3/20 (15.0%) |
| phosphonic acid derivative | FOF             |            |        |       |         |     | 0/8 (0%) | 1/4 (25%) | 0/2 (0%) | 0/1 (0%) | N.A. | 0/5 (0%) | 1/20 (5.0%) |
| pseudomonic acid derivative | MUP *             |            |        |       |         |     | 1/10 (10%) | 0/2 (0%) | N.A. | N.A. | 0/5 (0%) | 0/1 (0%) | 1/18 (5.0%) |
| rifampicins         | RIF *              |            |        |       |         |     | 13/18 (72.2%) | 2/6 (33.3%) | 0/2 (0%) | 0/1 (0%) | 0/5 (0%) | 0/6 (0%) | 15/38 (39.5%) |
| nitrofuran derivative | NIT              |            |        |       |         |     | 0/10 (0%) | 0/2 (0%) | N.A. | N.A. | 0/5 (0%) | 0/1 (0%) | 0/18 (0%) |
| amphenicols         | CHL                |            |        |       |         |     | 0/10 (0%) | 0/2 (0%) | N.A. | N.A. | 0/5 (0%) | 0/1 (0%) | 0/18 (0%) |
|                     | FLO                |            |        |       |         |     | 0/6 (0%) | N.A. | N.A. | N.A. | 0/3 (0%) | 0/2 (0%) | 0/11 (0%) |
| sulfonamides        | SXT                |            |        |       |         |     | 0/24 (0%) | 0/6 (0%) | 0/2 (0%) | 0/1 (0%) | 0/8 (0%) | 0/8 (0%) | 0/49 (0%) |
| tetracyclines       | TET                |            |        |       |         |     | 11/24 (45.8%) | 1/6 (16.7%) | 0/2 (0%) | 0/1 (0%) | 6/8 (75%) | 1/8 (12.5%) | 19/49 (38.8%) |
|                     | TGC                |            |        |       |         |     | 0/8 (0%) | 0/4 (0%) | 0/2 (0%) | 0/1 (0%) | N.A. | 0/5 (0%) | 0/20 (0%) |

Legend: PCG—benzylpenicillin; OXA—oxacillin; AMP—ampicillin; IPM—imipenem; SAM—ampicillin/sulbactam; CET—cefalotin; CTF—ceftriaxone; CEF—cefequinone; GEN—gentamicin; KAN—kanamycin; AMK—amikacin; NEO—neomycin; CIP—ciprofloxacin; MXF—moxifloxacin; ENR—enrofloxacin; FA—fusidic acid; TEC—teicoplanin; VAN—vancomycin; CLI—clindamycin; ERY—erythromycin; TMS—tilmicosin; TLY—tulathromycin; LZD—linezolid; FOF—fosfomycin; MUP—mupirocin; RIF—rifampicin; NIT—nitrofurantoin; CHL—chloramphenicol; FLO—florfenicol; SXT—trimethoprim— sulfamethoxazole; TET—tetracycline; TGC—tigecycline; N.A.—not applicable; * antimicrobials expressed intermediate MIC results, which were counted as resistant—RIF (n = 11), CTF (n = 8), NEO (n = 5), CIP (n = 4), MUP (n = 1), and TEC (n = 1).
Twenty isolates tested with the AST-P592 card expressed resistance in descending order towards RIF (50%), PCG (40%), CIP (30%), CLI (25%), TEC (25%), OXA (20%), FA (20%), IPM (15%), ERY (15%), LZD (15%), TET (15%), VAN (10%), and FOF (5%), but all the isolates were susceptible to GEN, MXF, SXT, and TGC (Table 2, Supplementary Materials Table S1). Furthermore, the exhibited antimicrobial susceptibility profile of another 18 isolates screened with the AST-GP69 card showed that the resistance to ENR (77.8%) was the most common, followed by that to TET (44.4%), PCG (38.9%), RIF (27.8%), KAN (11.1%), OXA (5.6%), VAN (5.6%), AMP (5.6%), IPM (5.6%), FA (5.6%), and MUP (5.6%), but none of the isolates were resistant to SAM, GEN, MBX, ERY, CLI, NIT, CHL, and SXT (Table 2, Supplementary Materials Table S2). Concerning the monitoring of drug resistance of 11 S. aureus isolates using the AST-GP79 card, resistance was observed towards PCG (100%), ENR (100%), KAN (90.9%), AMK (90.9%), CLI (90.9%), CTF (72.7%), ERY (72.7%), TET (72.7%), NEO (63.6%), TMS (36.4%), OXA (27.3%), TYL (18.2%), and GEN (18.2%), whereas total susceptibility was recorded for AMP, CET, CEF, FLO, and SXT (Table 2, Supplementary Materials Table S3).

Twenty-four (49%, 95% CI 35.6–62.5) out from 49 tested S. aureus isolates exhibited MDR (telemea origin S. aureus strains to 3–8 classes; cas—to 3–7 classes) resulting in the expression of a total of 20 resistance profiles (Table 3), while four (8.2%) strains were susceptible to all tested drugs. No notable associations ($p < 0.05$) were registered between the expressions of the antimicrobial resistance patterns of the tested S. aureus isolates and their isolation sources.
### Table 3. Multi-drug resistance phenotype combination of the tested *S. aureus* isolates.

| Cheese Assortments and Their Milk Origin | No. of Isolates | Resistance to Antimicrobial Profile of *S. aureus* Strains (No.) | No. of Classes with Resistance | Classes with Resistance |
|-----------------------------------------|----------------|----------------------------------------------------------------|------------------------------|------------------------|
| Sheep milk                              |                | PCG, OXA, IPM, FA, TEC, VAN, CLI, ERY, LZD, RIF, TET (11)       | 8                            | β-lactams, glycopeptides, steroids, lincomycins, macrolides, oxazolidinones, rifampicins, tetracyclines |
|                                        | 1              | PCG, OXA, AMP, IPM, ENR, VAN, FA, MUP, RIF, TET (10)           | 7                            | β-lactams, quinolones, glycopeptides, steroids, pseudomonic acid derivative, rifampicins, tetracyclines |
|                                        | 2              | PCG, CTF, KAN, AMK, NEO, ENR, ERY, CLI, TET (9)                | 6                            | β-lactams, aminoglycosides, quinolones, macrolides, lincomycins, tetracyclines |
|                                        | 2              | PCG, CTF, KAN, AMK, ENR, ERY, CLI, TET (8)                    |                              |                        |
|                                        | 1              | PCG, OXA, GEN, KAN, AMK, NEO, ENR, TMS, TYL, CLI (10)         | 5                            | β-lactams, aminoglycosides, quinolones, macrolides, lincomycins |
|                                        | 1              | PCG, CL, CLI, ERY, RIF, TET (5)                              |                              |                        |
|                                        | 2              | PCG, ENR, TET, RIF (4)                                      | 4                            | β-lactams, quinolones, rifampicins, tetracyclines |
|                                        | 1              | PCG, KAN, ENR, TET (4)                                      |                              |                        |
|                                        | 1              | PCG, OXA, ENR, TMS (4)                                       | 3                            | β-lactams, quinolones, macrolides |
|                                        | 1              | PCG, CIP, RIF (3)                                            |                              | β-lactams, quinolones, rifampicins |
|                                        | 1              | PCG, OXA, IPM, CIP, RIF (5)                                  |                              |                        |
|                                        | 1              | PCG, KAN, TET (3)                                            |                              |                        |
|                                        | 1              | PCG, OXA, IPM, FA, TEC, VAN, CLI, ERY, LZD, RIF (10)         | 7                            | β-lactams, glycopeptides, steroids, lincomycins, macrolides, oxazolidinones, rifampicins |
|                                        | 1              | PCG, FA, CIP, CLI, TET (3)                                   | 3                            | β-lactams, aminoglycosides, quinolones, rifampicins, lincomycins |
|                                        | 1              | PCG, KAN, AMK, NEO, ENR, ERY, CLI, TET (9)                   | 6                            | β-lactams, aminoglycosides, quinolones, macrolides, lincomycins, tetracyclines |
| Cow milk                               |                | PCG, KAN, AMK, NEO, ENR, ERY, TMS, TYL, CLI (9)              | 5                            | β-lactams, aminoglycosides, quinolones, macrolides, lincomycins |
|                                        | 2              | PCG, CTF, KAN, AMK, NEO, ENR, ERY, CLI, TET (8)              | 6                            | β-lactams, aminoglycosides, quinolones, macrolides, lincomycins, tetracyclines |
|                                        | 1              | PCG, OXA, GEN, KAN, AMK, ENR, TMS, TYL, CLI (9)              | 5                            | β-lactams, aminoglycosides, quinolones, macrolides, lincomycins |

Legend: PCG—benzylpenicillin; OXA—oxacillin; AMP—ampicillin; IPM—imipenem; SAM—ampicillin/sulbactam; GEN—gentamicin; KAN—kanamycin; AMK—amikacin; NEO—neomycin; ENR—enrofloxacin; FA—fusidic acid; TEC—teicoplanin; VAN—vancomycin; CLI—clindamycin; ERY—erythromycin; TMS—tilmicosin; TYL—tylosin; LZD—linezolid; FOF—fosfomycin; MUP—mupinocin; RIF—rifampicin; FLO—fiorfenicol; TET—tetracycline.
3. Discussion

To the authors’ knowledge, this is the first extended study in Romania investigating the presence and public health significance of the CPS in traditional cheese assortments destined for human consumption. As has been highlighted in several previously conducted investigations, CPS could be isolated from the raw milk origin cheese assortments by a wide range of frequencies and counts. Thus, the recorded prevalence for CPS contamination in the present study (81.6%) is lower than that reported in neighboring Serbia (87.4%; [4]), but higher than that obtained in Poland (69.2%; [11]), Sweden (69%; [12]), Italy (23.7%; [13]), or in another recent conducted survey in Serbia (20.5%; [6]). Variations of the recorded results can be related upon by the microbiological quality of the raw milk and level of hygienic measures in the farmhouse establishments during cheese production. The recorded relatively high frequency of isolation of CPS in the present study, reflects the low control measures applied during the cheese-making process by producers, including handling of the curd without gloves, face mask or head cover [4,11,12]. In addition, within the main obtaining technological steps (e.g., milk coagulation, curd processing, pressing or early ripening) the unrestricted direct exposure of the assortments to the environment (e.g., air, dust, food contact surfaces) can greatly contribute to the increasing of the amount of mesophilic halotolerant staphylococci in the final product [4].

Ninety-four (68.1% 95% CI 59.9–75.3) samples harbored CPS levels above the regulatory limit of \(>10^5\) established by the European Regulation (EC) No. 2073/2005 modified by the Regulation (EC) No. 1441/2007 [14]. Accordingly, in case of such contamination level SEs must be screened. As has been previously demonstrated, the low generation time of staphylococci (0.8 h at 25°C) resulting in their rapid growth in the milk, favored by their physical entrapment by the curd can be considered explanations for the recorded high contamination level [10]. These findings demonstrate the unsuccessful implementation of adequate hygiene measures by the majority of manufacturers, resulting in potentially hazardous products to consumers.

Similar to our results, other \(S.\ aureus\) surveys conducted in different cheese types yielded positive findings in Croatia (54%; [15]), Scotland (33%; [16]), Poland (69.2%; [11]), and Brazil (70%; [17]). As has been previously concluded, these bacteria may be introduced in the raw milk and subsequently in dairy products in several ways such as (i) directly from the udder level with clinical or subclinical staphylococcal mastitis, (ii) accidental fecal contamination, (iii) milking equipment or (iv) skin of the personnel involved in cheese production [18,19]. The resultant overall frequency of isolation rate of \(S.\ aureus\), able to produce heat stable toxins in food, strengthens the need of an integrated surveillance system at the level of production units to avoid the transmission of this pathogen within traditional cheeses.

The \(\textit{mecA}\) gene is the genotypic determinant of MRSA strains, encoding the PBP2a synthesis which phenotypically reflect in MIC values higher than 4 \(\mu g/mL\) for oxacillin [20]. In agreement with our results, positive findings, with relatively low detection rate of the \(\textit{mecA}\) gene in cheese origin \(S.\ aureus\), were reported in studies conducted in Iran (16.2%, [21]), Italy (1.3%, [22]; 3.8%, [23]) or Switzerland (0.2%, [24]). Contrary, a number of investigations reported that none of the tested \(S.\ aureus\) isolates were \(\textit{mecA}\) positive [4,25,26]. The finding of the present survey pointed out that the consumption of raw milk origin traditional cheeses in the screened area can constitute a potential risk for the acquiring of MRSA strains, with subsequent possible challenges for public health specialists.

Even if the ELFA-Vidas\textsuperscript{®} \textit{Staph enterotoxin II} method is recognized as a sensitive assay [27], contrary to our results, other studies reported negative findings in the detection of SEs in cheese samples contaminated with a high level of CPS [11,28]. The variations in toxin detection may be related to the existence/absence of appropriate environmental conditions (e.g., temperature) [11]. Nevertheless, the obtained results provide an objective assessment of the real toxicity risk for human health.

This is the first report about the antimicrobial susceptibility testing of the cheese origin \(S.\ aureus\) isolates. Overall, the expressed resistance pattern of the tested strains revealed
increased resistance towards some drugs and decreased or total susceptibility to others. Concerning the seven antimicrobials, included in all of the used three specific cards, with which all of the S. aureus isolates were tested with different MIC range values, the highest resistances were observed towards PCG (53.1%) and TET (38.8%). Similar to our results, considerable AMR trends were recorded for penicillin in Serbia (66.6%, [4]) and Poland (50.8%, [11]); and for TET in Iran (56.1%, [21]) and China (98.1%, [29]). In addition, even if the recorded resistance level for CLI (30.6%), ERY (22.4%), OXA (16.3%) and GEN (4.1%) can be accounted as moderate or relatively low, the study findings indicated the possible over-usage of these drugs in the Romanian livestock veterinary medicine and an urgent adaptation of an efficient antimicrobial stewardship programs. Contrary to our results, in other studies a total susceptibility has been noted for CLI [4], OXA [29], and ERY [30].

Unfortunately, 90.1% (10 out from 11 tested isolates), 86.2% (25/29), 72.7% (8/11), 63.6% (7/11), 41.4% (12/29), 39.5% (15/38), and 36.4% (4/11) of a certain number of tested isolates showed resistance to AMK, ENR, CTF, NEO, KAN, RIF, and TMS consecutively (Table 2). These results are comparable to those reported in other investigations [4,11,21,29,30]. The recorded increased resistance patterns can be considered another proof of the undesired outcomes of the intensive and irrational use of these drugs to control and treat infections in milk producing animals. Furthermore, these findings are in correlation with antibiotics that are regularly used for treatment of livestock infections in Romania (Imre, unpublished results).

The recorded high number of MDR S. aureus isolates (49%) is another notable finding of the present survey. Usually, the use of a drug to which a bacterium has expressed an intermediate level of resistance in the management of infections caused by that bacterium is associated with an uncertain therapeutic effect. Also, the intermediate category signals the need for a higher dose than the standard one, favoring the development of antibiotic resistance [1]. Based on these considerations and to avoid undesired outcomes of the treatment of S. aureus infections by physicians and veterinary practitioners, in the present study the obtained intermediate resistance levels in the case of some drugs (RIF, CTF, NEO, CIP, MUP, TEC) were considered as resistant (Table 2). In this regard, it is important to mention that the consideration of intermediate MIC results as resistant towards a certain drug resulted in the reporting of more resistance within the tested S. aureus strains. Our results, in general, confirm the steady upward trend of AMR phenomenon reported in other earlier studies for food and/or animal origin strains. Thus, in the neighboring Serbia, 25.0% of the tested isolates expressed MDR and the most frequently encountered resistance profiles included PCG, CIP, or GEN [4]. In another investigation, a total of 12.8% of the screened milk and dairy products origin S. aureus isolates were MDR [21]. In addition, in context of the One Health approach, the recorded worrying 100% MDR pattern in case of S. aureus strains isolated from shelter dogs with skin lesions from Timisoara Municipality, included in the monitored Banat region in the present study, indirectly suggests the increased AMR trend in case of this pathogen in Romania [31]. In contrast, in a study conducted in Poland most of the isolates (47.5%) were found to be resistant to only one antimicrobial [11].

Three (7.9%) out from 38 tested S. aureus strains in the present study were resistant to VAN. This worrying result derives from the fact that this glycopeptide antibiotic, during the last decades, has been considered to be a mainstay first line drug in the treatment of invasive MRSA infections. The emergence of the complete vancomycin-resistant S. aureus (VRSA) strains, conferred by the vanA gene, has been identified, for the first time, in 2002 in Michigan, USA [32]. To date, a total of 52 VRSA strains carrying the vanA gene have been reported worldwide (reviewed by [33]). It is important to mention that the acquiring of VAN resistance in the case of S. aureus can be closely related to the presence of the vanA gene clusters and several mobile genetic elements (e.g., self-transferable or mobilizable plasmids, conjugative transposons) in other Gram-positive bacteria (e.g., Enterococcus faecalis, E. faecium, Clostridium difficile) [34]. Until now, VAN resistance has not been reported for food origin S. aureus strains in Romania, but its occurrence has been recently confirmed for strains isolated from shelter dogs with skin lesions [31]. Further molecular studies
focusing on the evidence of the \textit{vanA} gene in a large number of food or animal origin \textit{S. aureus} isolates are still required to improve our understanding about the demonstrated spreading of VAN resistance by this pathogen in Romania.

4. Materials and Methods

4.1. Sample Collection

A total of 169 Romanian traditional raw milk cheese specimens, providing from small scale integrated dairy production units and exposed directly for sale, were collected between February 2012 and October 2013, and January 2020 and February 2021, from nine agri-food markets located in urban settlements of the historical Banat region (NW—\(46^\circ 6’39.38”\N, 20^\circ 16’37.12”\E; NE—\(45^\circ 56’55.70”\N, 22^\circ 17’40.37”\E; SE—\(44^\circ 46’35.53”\N, 22^\circ 31’27.89”\E; SW—\(45^\circ 21’18.06”\N, 21^\circ 0’2.92”\E), South-Western part of Romania. The total number of samples to be collected (\(n = 169\)) was determined using the proposed formula by Cochran (1963), with 87.4\% expected prevalence, 5\% absolute precision (confidence level), and 95\% confidence interval (CI) [35]. Also, sample collection followed the requirement of the European Regulation (EC) No. 2073/2005, meaning that for each sample, a pool of the randomly selected five products (approx. ~300 g from each), from the same category and retailer were collected. The selected agri-food markets were located in the two county (Timiș and Caraș-Severin) residences of the assessed region, namely Timișoara (\(n = 6\)) and Resița (\(n = 3\)) municipalities, being visited daily by hundreds of consumers. The samples were aseptically collected by the research team members, in the first month of each trimester of the calendar year, accompanying the veterinary authorities during the officially organized control visits. The raw milk cow and/or sheep origin cheese samples (see their distribution in Table 1) included the following four assortments: telemea (\(n = 109\))—white brined soft cheese; caș (\(n = 38\))—semisoft, unsalted fresh cheese; burduf (\(n = 11\))—slightly soft kneaded cheese; and urdă (\(n = 11\))—fresh whey cheese. The collected samples were individually placed into a sterile disposable plastic bag and labeled with the assortment name, sampling date and location. In the same day, the samples were transported under refrigeration conditions (\(\leq 4^\circ \text{C}\)) to the laboratory of Food Hygiene and Microbiological Risk Assessment of the Faculty of Veterinary Medicine, Timișoara for microbiological analysis.

4.2. Isolation and Enumeration of Coagulase-Positive Staphylococci (CPS) and Identification of \textit{S. aureus}

The isolation and enumeration of CPS was performed following the International Organization and Standardization (ISO) 6888-1:2021 standard with slight modifications [36]. In brief, 10 g of each sample was homogenized in a Stomacher (bioMérieux, Marcy l’Etoile, France) (90 s) with 90 mL of preheated (\(45^\circ \text{C}\)) peptone-buffered solution (PBS; pH = 7.5 ± 0.1). Next, samples were serially diluted in sterile 0.5\% peptone water up to \(10^{-4}\) (1:10,000) dilution. Aliquots of 0.1 mL from each dilution were further cultured on the selective and differential Baird–Parker agar supplemented with egg yolk tellurite emulsion (Oxoid, Basingstoke, Hampshire, UK) medium at 37 °C for 36–48 h. The samples which produced typical colonies (i.e., convex black circular colonies surrounded by a transparent and/or opaque halo), of which number were counted, were considered to contain CPS. The number of typical colonies was assessed using the manual counting of colony-forming (CFU) units’ technique, recommended for estimating the number of viable bacteria cells. Five colonies from each positive plate were randomly selected, transferred and cultured on Brain Heart Infusion Agar (Biokar Diagnostics, Allone, France) at 37°C for 24 h. After growth, the presumptive \textit{Staphylococcus} spp. isolates were examined using Gram staining, coagulase, and catalase test. Subsequently, isolates were identified at species level by testing their complete biochemical properties with the Vitek2 automated compact system (bioMérieux, Marcy l’Etoile, France), and using the Vitek2® ID-GP (Gram-positive) specific identification cards, following the manufacturer guidelines.
4.3. Molecular Analyses

One S. aureus isolate per positive sample were directly subjected to molecular processing. Bacterial genomic DNA was isolated using a PureLink™ Genomic DNA Mini Kit (Invitrogen™, Carlsbad, CA, USA) following the manufacturer’s instructions. Firstly, molecular characterization of the isolates was accomplished through a genus-specific conventional uniplex polymerase chain reaction (PCR), targeting the 16S rDNA gene (~886 bp) and using the 16S-1 (5’-GTGCCAGCACGCCGGTAA-3’) and 16S-2 (5’-AGACCCCCGAACGTATTCAC-3’) primer set. Next, in order to evidence the nuc gene (~255 bp), specific to S. aureus encoding a thermostable nuclease (TNase), another PCR protocol was carried out implicating the specific nuc-1 (5’-TCAGCAAA TGCA TCACAAACAG-3’) and nuc-2 (5’-CGT AAA TGCACTTGCTTCAGG-3’) primers. Subsequently, the presence of mecA gene (533 bp), which confers resistance to methicillin encoding the penicillin-binding protein 2a (PBP2a) of S. aureus, were screened using the specific mecA-1 (5’-GGGA TCA T AGCGTCA TT A TTC-3’) and mecA-2 (5’-AACGA TGTGACACGA T AGCC-3’) primer set. PCR reaction mix and cycling conditions was established as indicated by Poulsen et al. [37]. Within each PCR assays the S. aureus ATCC 25923™ mecA positive strain was used as positive control, and PCR grade water (no template DNA) as negative control. The resultant PCR products were visualized on Midori Green (Nippon Genetics®; Europe, Gmbh, Düren, Germany) stained 1.8% agarose gel.

4.4. Enterotoxin Detection

Cheese samples (n = 94) with CPS contamination level higher than $10^5\log\text{CFU g}^{-1}$, being considered necessary for assumptive enterotoxin production [38], were screened for the presence of classical staphylococcal enterotoxins (SEs) using the Vidas® Staphylococcal enterotoxin II (SET2, bioMérieux, Marcy l’Etoile, France) assay, performed with the Mini VIDAS (bioMérieux, Marcy l’Etoile, France) automated system according to the manufacturer instructions. The methodology, based on Enzyme Linked Fluorescent Assay (ELFA) technique using anti-SEs antibodies, allows the simultaneous detection of seven SEs serotypes (A, B, C₁, C₂, C₃, D and E), with a limit of detection of 0.25 ng/g of food matrix. The system automatically quantifies the results as positive or negative.

4.5. Antimicrobial Susceptibility Testing

Antimicrobial susceptibility testing of the cheese origin S. aureus isolates (n = 49) was performed with the fully automated Vitek2 equipment (bioMérieux, Marcy l’Etoile, France). In this regard, three different Gram-positive specific bacteria cards were used. Each of them was selected in a certain interval of the study period, depending on their commercial availability and aiming to cover both livestock and human origin antimicrobials. Thus, the AST-P592, AST-GP69, and AST-GP79 Gram positive specific bacteria cards were used in the testing of the antimicrobial susceptibility profile of 20, 18, and 11 isolates, respectively (Tables S1–S3). These cards included a total of 33 antimicrobials (aminicacin [AMK], ampicillin [AMP], ampicillin/sulbactam [SAM], benzylpenicillin [PCG], cefalotin [CEF], ceftiofur [CTF], chloramphenicol [CHL], ciprofloxacin [CIP], clindamycin [CLI], enrofloxacin [ENR], erythromycin [ERY], florfenicol [FLO], fosfomycin [FOF], fusidic acid [FA], gentamicin [GEN], imipenem [IPM], kanamycin [KAN], linezolid [LZD], marbofloxacin [MBX], moxifloxacin [MXF], mupirocin [MUP], neomycin [NEO], nitrofurantoin [NIT], oxacinil [OXA], rifampicin [RIF], teicoplanin [TEC], tetracycline [TET], tigecycline [TGC], tilmicosin [TMS], trimethoprim-sulfamethoxazole [SXT], tylosin [TYL], vancomycin [VAN]), with a correspondent minimum inhibitory concentration [MIC] range, from 15 classes (aminoglycosides, amphenicols, fluoroquinolones, glycopeptides, lincomycins, macrolides, nitrofuran derivates, oxazolidinones, phosphonic acid derivaties, pseudomonic acid derivates, quinolones, rifamycins, β-lactams, steroids, sulfonamides and tetracyclines), as indicated in the Tables S1–S3, respectively. The isolates were categorized by the Vitek2 equipment as susceptible, intermediate or resistant to the tested antimicrobials. The isolates tested intermediate to a certain drug were considered resistant, and the MDR phenomenon was quantified based on the acquired resistance to at least one antimicrobial in three or more antimicrobial classes [39]. Resistance breakpoints were established according
to the Clinical Laboratory Standards Institute (CLSI) guideline [20]. Within determinations, the internal quality control was performed with the *S. aureus* ATCC 29213™ strain.

### 4.6. Statistical Analysis

The obtained data were statistically analyzed using the SPSS software version 20.0 (IBM, Armonk, NY, USA). Differences in the frequency of isolation of *S. aureus* strains in relation to their sample origin were estimated using the Pearson’s chi-square test and were considered significant at \( p \leq 0.05 \).

### 5. Conclusions

The results of the present study have increased our knowledge about the frequency of isolation of CPS, *S. aureus* and SEs in different traditional Romanian cheeses in the screened region, reflecting hygienic deficiencies during their manufacturing. The occurrence of multidrug-, methicillin-, and vancomycin-resistant *S. aureus* strains, with variable detection rate in the monitored cheese assortments, indicates a substantial public health and medical concern, and the possible over-use of some drugs in the livestock breeding industry. Likewise, the findings could reflect the increased monitoring of the biological safety of these products by veterinary authorities, and can provide useful insight for veterinarians and physicians in the management of *S. aureus* infections. The present study offers baseline information on the knowledge of the phenotypic antimicrobial resistance of food origin *S. aureus* strains in the screened region. However, further studies based on molecular tools, investigating the presence of other antibiotic resistance genes and mobile genetic elements responsible for genetic material transfer between *S. aureus* strains, are still necessary to obtain a better knowledge of the complex puzzle of the AMR phenomenon of this important food-borne pathogen in Romania.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/antibiotics10121458/s1, Table S1: Origin, antimicrobial resistance (full circles) and susceptibility (empty circles) profile of the tested *S. aureus* strains with the AST-P592 card, and isolated in the period February 2012 and October 2013, Table S2: Origin, antimicrobial resistance (full circles) and susceptibility (empty circles) profile of the tested *S. aureus* strains with the AST-GP69 card, and isolated in the period February 2012 and October 2013, Table S3: Origin, antimicrobial resistance (full circles) and susceptibility (empty circles) profile of the tested *S. aureus* strains with the AST-GP79 card, isolated in the period January 2020–February 2021.

**Author Contributions:** Conceptualization, methodology, data curation, writing—original draft preparation, A.M., S.M.A.-E.; investigation, software, formal analysis, visualization, A.B.-C., E.T.; supervision, funding acquisition, writing—review and editing K.I., K.I.S.; resources, data curation VH. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Data Availability Statement:** All data generated or analyzed during this study are included in the submitted version of the manuscript.

**Acknowledgments:** The authors gratefully acknowledge the support of Banat’s University of Agricultural Sciences and Veterinary Medicine “King Michael I of Romania” from Timișoara and Research Institute for Biosecurity and Bioengineering Timișoara, Romania supporting the paper publication from the own funds.

**Conflicts of Interest:** The authors declare no conflict of interest.
References
1. Turner, N.A.; Sharma-Kuinkel, B.K.; Maskarinec, S.A.; Eichenberger, E.M.; Shah, P.P.; Carugati, M.; Holland, T.L.; Fowler, V.G., Jr. Methicillin-resistant Staphylococcus aureus: An overview of basic and clinical research. Nat. Rev. Microbiol. 2019, 17, 203–218. [CrossRef]
2. Wagner, S.; Erskine, R. Antimicrobial drug use in mastitis. In Antimicrobial Therapy in Veterinary Medicine, 5th ed.; Wiley-Blackwell Publishing: Ames, IA, USA, 2013; pp. 519–528.
3. Pexara, A.; Solomakos, N.; Sergelidis, D.; Angelidis, A.; Govaris, A. Occurrence and antibiotic resistance of enterotoxigenic Staphylococcus aureus in raw ovine and caprine milk in Greece. Dairy Sci. Technol. 2016, 96, 345–357. [CrossRef]
4. Bulajic, S.; Colovic, S.; Misic, D.; Djordjevic, J.; Savic-Radovanovic, R.; Asanin, J.; Ledina, T. Enterotoxin production and antimicrobial susceptibility in Staphylococci isolated from traditional raw milk cheeses in Serbia. J. Environ. Sci. Health B 2017, 52, 864–870. [CrossRef]
5. Angelidis, A.S.; Komodromos, D.; Giannakou, R.; Arsenos, G.; Gelasakis, A.I.; Kyritsi, M.; Hadjichristodoulou, C.; Torounidou, P.; Papa, A.; et al. Isolation and characterization of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA) from milk of dairy goats under low-input farm management in Greece. Vet. Microbiol. 2020, 247, 108749. [CrossRef]
6. Radoslava, S.R.; Zdravković, N.; Velebit, B. Occurrence and characterization of enterotoxigenic Staphylococci isolated from soft cheeses in Serbia. Acta Vet. 2020, 70, 238–254. [CrossRef]
7. European Food Safety Authority. Scientific report of EFSA and ECDC. The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food, 2017. EFSA J. 2019, 17, 5598. [CrossRef]
8. Onciuc, E.A.; Ariza-Miguel, J.; Bolocan, A.S.; Diez-Valcarce, M.; Rovira, J.; Hernández, M.; Fernández-Natal, I.; Nicolau, A.I.; Rodríguez-Lázaro, D. Foods from black market at EU border as a neglected route of potential methicillin-resistant Staphylococcus aureus transmission. Int. J. Food Microbiol. 2015, 209, 34–38. [CrossRef]
9. Ciocâlu, L.; Nicolau, A.I.; Wagner, M.; Rychli, K. Listeria monocytogenes isolated from food samples from a Romanian black market show distinct virulence profiles. Int. J. Food Microbiol. 2015, 200, 44–51. [CrossRef]
10. Le Marc, Y.; Valik, L.; Medved’ová, A. Modelling the effect of the starter culture on the growth of Staphylococcus aureus in milk. Int. J. Food Microbiol. 2009, 129, 306–311. [CrossRef]
11. Rola, J.G.; Czubkowska, A.; Korpysa-Dzirba, W.; Osek, J. Occurrence of Staphylococcus aureus on Farms with Small Scale Production of Raw Milk Cheeses in Poland. Toxins 2016, 8, 62. [CrossRef]
12. Rosengren, A.; Fabricius, A.; Guss, B.; Sylven, S.; Lindqvist, R. Occurrence of foodborne pathogens and characterization of Staphylococcus aureus contamination on farm-dairies. Int. J. Food Microbiol. 2010, 144, 263–269. [CrossRef]
13. Normanno, G.; Finiu, A.; Virgilio, S.; Mula, G.; Dambrosio, A.; Decastelli, L.; Mioni, R.; Scuota, S.; Bolzoni, G.; et al. Coagulase-positive Staphylococci and Staphylococcus aureus in food products marketed in Italy. Int. J. Food Microbiol. 2005, 98, 73–79. [CrossRef] [PubMed]
14. FAO. Commission Regulation (EC) No 2073/2005 of 15 November 2005 on microbiological criteria for foodstuffs. Off. J. Eur. Union 2005, L338, 1–26. Available online: http://data.europa.eu/eli/reg/2005/2073/oj (accessed on 1 November 2021).
15. Samardži, D.; Damjanović, S.; Pogačić, T.S. Staphylococcus aureus u siru. Mlijekarstvo 2007, 57, 31–48.
16. Williams, A.G.; Withers, S.E. Microbiological characterization of artisanal farm house cheeses manufactured in Scotland. Int. J. Dairy Technol. 2010, 63, 356–369. [CrossRef]
17. Barelli, B.M.; Ferreira, E.G.; Lacerda, I.C.A.; Santos, D.A.; Carmo, L.S.; Dias, R.S.; Silva, M.C.C.; Rosa, C.A. Enterotoxigenic Staphylococcus spp. and some other microorganisms during production of canastra cheese, Brazil. Braz. J. Microbiol. 2006, 37, 545–550. [CrossRef]
18. André, M.C.D.P.B.; Campos, M.R.H.; Borges, L.J.; Kipnis, A.; Pimenta, F.C.; Serafimi, A.B. Comparison of Staphylococcus aureus isolates from food handlers, raw bovine milk and Minas Frescal cheese by antibiogram and pulsed-field gel electrophoresis following Smal digestion. Food Control. 2009, 19, 200–207. [CrossRef]
19. Callon, C.; Gilbert, F.B.; Cremoux, R.D.; Montel, M.C. Application of variable number of tandem repeat analysis to determine the origin of Staphylococcus aureus contamination from milk to cheese in goat cheese farms. Food Control. 2015, 54, 383–388. [CrossRef]
20. Clinical and Laboratory Standard Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, CLSI document M100-S28, 28th ed. Clinical and Laboratory Standard Institute: Wayne, PA, USA, 2018.
21. Jamali, H.; Paydar, M.; Radmehr, B.; Ismail, S.; Dadrasnia, A. Prevalence and antimicrobial resistance of Staphylococcus aureus isolated from raw milk and dairy products. Food Control. 2015, 54, 383–388. [CrossRef]
22. Carfora, V.; Caprioli, A.; Marri, N.; Sagrafoli, D.; Boselli, C.; Giacinti, G.; Giangolini, G.; Sorbara, L.; Dottarelli, S.; Battisti, A.; et al. Enterotoxin genes, enterotoxin production, and methicillin resistance in Staphylococcus aureus isolated from milk and dairy products in central Italy. Int. Dairy J. 2015, 42, 12–15. [CrossRef]
23. Normanno, G.; Corrente, M.; Salandra, G.L.; Dambrosio, A.; Quaglia, N.C.; Parisi, A.; Greco, G.; Bellaccio, A.L.; Virgilio, S.; Celano, G.V. Methicillin resistant Staphylococcus aureus (MRSA) in foods of animal origin product in Italy. Int. J. Food Microbiol. 2007, 117, 219–222. [CrossRef] [PubMed]
24. Hummerjohann, J.; Naskova, J.; Baumgartner, A.; Graber, H.U. Enterotoxin producing Staphylococcus aureus Genotype B as a major contaminant in Swiss raw milk cheese. J. Dairy Sci. 2014, 97, 1305–1312. [CrossRef]
25. Spanu, V.; Virdis, S.; Scarano, C.; Cossu, F.; De Santis, E.P.L.; Cosseddu, A.M. Antibiotic resistance assessment in Staphylococcus aureus strains isolated from raw sheep’s milk cheese. Vet. Res. Commun. 2010, 34, 87–90. [CrossRef] [PubMed]
26. Zinke, C.; Winter, M.; Mohr, E.; Krömker, V. Occurrence of methicillin-resistant Staphylococcus aureus in cheese produced in German Farm-Dairies. *Ada. Microbiol.* 2012, 2, 629–633. [CrossRef]

27. Hennekinne, J.A.; De Buyser, M.L.; Dragacci, S. Staphylococcus aureus and its food poisoning toxins: Characterization and outbreak investigation. *FEMS Microbiol. Rev.* 2012, 36, 815–836. [CrossRef]

28. Dores, M.T.; Dias, R.S.; Arcuri, E.F.; Nobrega, J.E.; Ferreira, C.L.L.F. Enterotoxigenic potential of Staphylococcus aureus isolated from artisanal Minas cheese from the Serra da Canastra-MG, Brazil. *Food Sci. Technol.* 2013, 33, 271–275. [CrossRef]

29. Gao, J.; Ferreri, M.; Yu, F.; Liu, X.; Chen, L.; Su, J.; Han, B. Molecular types and antibiotic resistance of Staphylococcus aureus isolates from bovine mastitis in a single herd in China. *Vet. J.* 2012, 192, 550–552. [CrossRef] [PubMed]

30. Spanu, V.; Scarano, C.; Cossu, F.; Pala, C.; Spanu, C.; de Santis, E.P.L. Antibiotic Resistance Traits and Molecular Subtyping of Staphylococcus aureus Isolated from Raw Sheep Milk Cheese. *J. Food Sci.* 2014, 79, M2066–M2071. [CrossRef] [PubMed]

31. János, D.; Viorel, H.; Ionica, I.; Corina, P.; Tiana, F.; Roxana, D. Carriage of Multidrug Resistance Staphylococci in Shelter Dogs in Timisoara, Romania. *Antibiotics* 2021, 10, 801. [CrossRef] [PubMed]

32. Chang, S.; Sievert, D.M.; Hageman, J.C.; Boulton, M.L.; Tenover, F.C.; Downes, F.P.; Shah, S.; Rudrik, J.T.; Pupp, G.R.; Brown, W.J.; et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. *N. Engl. J Med.* 2003, 348, 1342–1347. [CrossRef]

33. Cong, Y.; Yang, S.; Rao, X. Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features. *J. Adv. Res.* 2020, 21, 169–176. [CrossRef]

34. Hong, H.J.; Hutchings, M.I.; Buttner, M.J. Biotechnology and biological sciences research council, UK, 2008. Vancomycin resistance VanS/VanR two-component systems. *Adv. Exp. Med. Biol.* 2008, 631, 200–213. [CrossRef] [PubMed]

35. Cochran, W.G. *Sampling Technique*, 2nd ed.; John Wiley and Sons Inc.: New York, NY, USA, 1963.

36. International Organization for Standardization. *Microbiology of the Food Chain—Horizontal Method for the Enumeration of Coagulase-Positive Staphylococci (Staphylococcus aureus and Other Species)—Part 1: Method Using Baird-Parker Agar Medium; ISO 6888-1:2021-08; International Organization for Standardization: Geneva, Switzerland, 2021.

37. Poulsen, A.B.; Skov, R.; Pallesen, L.V. Detection of methicillin resistance in coagulase-negative staphylococci and in staphylococci directly from simulated blood cultures using the EVIGENE MRSA detection kit. *J. Antimicrob. Chemother.* 2003, 51, 419–421. [PubMed]

38. Bryan, F.L.; Guzewich, J.J.; Todd, E.C.D. Surveillance of foodborne disease II. Summary and presentation of descriptive data and epidemiologic patterns; their value and limitations. *J. Food Prot.* 1997, 60, 56–578. [CrossRef] [PubMed]

39. Magiorakos, A.P.; Srinivasa, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. *Clin. Microbiol. Infect.* 2012, 8, 268–281. [CrossRef] [PubMed]